Amicus Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Amicus Therapeutics's estimated annual revenue is currently $91.2M per year.
- Amicus Therapeutics received $300.0M in venture funding in February 2018.
- Amicus Therapeutics's estimated revenue per employee is $153,353
- Amicus Therapeutics's total funding is $843.1M.
- Amicus Therapeutics has 595 Employees.
- Amicus Therapeutics grew their employee count by 5% last year.
Amicus Therapeutics Competitors & AlternativesAdd Company
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Amicus Therapeutics?
Amicus Therapeutics is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. We have a unique set of platform technologies and medicines in development for patients living with the Lysosomal Storage Disorders Fabry disease and Pompe disease and we are committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for these and other rare diseases. The needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. Our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers. Several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. Our Amicus footprint spans 27 countries including our global headquarters in Cranbury, NJ and international headquarters in Gerrards Cross UK. Additional international office locations include Canada, Germany, Italy, The Netherlands, Spain, France, and Japan. More information about Amicus and our career opportunities can be found at www.amicusrx.com.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
Amicus Therapeutics News
Insider Selling: Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Sells 2,214 Shares of Stock. Posted by admin on Apr 20th, 2022.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Expected to Announce Quarterly Sales of $79.69 Million. Posted by admin on Apr 15th, 2022.
PHILADELPHIA, April 19, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company...
Amicus Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Updates 3Q21 Total Galafold® Revenue of $79.5M - an 18% increase over 3Q20 Reiterating 2021 Revenue Guidance of $300M-$315M AT-GAA BLA and NDA for Pompe Disease Accepted for Review by the U.S. FDA; Marketing Aut ...
PHILADELPHIA, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced the European Commission has approved Galafold® (migalastat) fo ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Amicus Therapeutics Funding
|2006-05-19||$86.2M||Undisclosed||Morgan Stanley, Goldman Sachs and Co||Article|
|2006-09-15||$60.0M||D||New Enterprise Associates||Article|
|2007-06-04||$60.0M||Undisclosed||Morgan Stanley and Co Incorpor, Merrill Lynch and Co||Article|
|2010-02-26||$18.5M||Undisclosed||Leerink Swann LLC||Article|
|2012-03-05||$54.0M||Undisclosed||Leerink Swann LLC , Cowen and Company LLC||Article|
|2014-01-02||$25.0M||Undisclosed||MidCap Financial, LLC||Article|
|2014-11-25||$103.5M||Undisclosed||J.P. Morgan Securities LLC||Article|
|2015-06-15||$258.8M||Undisclosed||J.P. Morgan Securities LLC||Article|
|2017-07-14||$258.8M||Undisclosed||J.P. Morgan Securities LLC||Article|
|2018-02-19||$300.0M||Undisclosed||BofA Merrill Lynch||Article|